Axio Biosolutions, a Boston and Bengaluru-based medical device company has raised $6 million in Series B2 led by TrueScale Capital, reports Inc. 42. Existing investors Omidyar Network India, University of California – Ratan Tata Fund, and Accel also participated in this funding round. With this deal, Sameer Nath, managing partner, TrueScale Capital, will join Axio’s board of directors.
Founded in 2007, the startup develops proprietary medical products using novel biomaterial-based technology for the hemostatic and advanced wound care market globally. Read more.
